Market Currents
Eli Lilly (LLY -1.2%) receives a blow in its attempts to overcome its patent expirations, saying...
-
Wednesday, July 11, 2012, 9:02 AM ETEli Lilly (LLY -1.2%) receives a blow in its attempts to overcome its patent expirations, saying its pomaglumetad methionil treatment for an acute exacerbation of schizophrenia missed the primary endpoint in a study. The company will await the results of two more trials before deciding its next steps.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
